Back
Myriad Genetics 10K Form
Sell
49
MYGN
Myriad Genetics
Last Price:
19.97
Seasonality Move:
3.18%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-07 | 10Q | MYGN/Myriad Genetics Quarterly |
| 2023-08-04 | 10Q | MYGN/Myriad Genetics Quarterly |
| 2023-05-04 | 10Q | MYGN/Myriad Genetics Quarterly |
| 2022-11-02 | 10Q | MYGN/Myriad Genetics Quarterly |
| 2022-08-05 | 10Q | MYGN/Myriad Genetics Quarterly |
| 2022-05-06 | 10Q | MYGN/Myriad Genetics Quarterly |
Receive MYGN News And Ratings
See the #1 stock for the next 7 days that we like better than MYGN
MYGN Financial Statistics
Sales & Book Value
| Annual Sales: | $753.2M |
|---|---|
| Cash Flow: | $-68.2M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $8.71 |
| Price / Book: | 2.29 |
Profitability
| EPS (TTM): | -3.20000 |
|---|---|
| Net Income (TTM): | $-263.3M |
| Gross Margin: | $517M |
| Return on Equity: | -33.56% |
| Return on Assets: | -22.5% |
Myriad Genetics Earnings Forecast
Key Myriad Genetics Financial Ratios
- The Gross Profit Margin over the past 28 years for MYGN is 68.64%.
- The Selling, General & Administrative Expenses for MYGN have been equal to 76.06% of Gross Profit Margin.
- The Research & Development expenses have been 11.78% of Revenue.
- The Interest Expense is -1.10% of Operating Income.
- The Net Earning history of MYGN is -34.96% of Total Revenues.
- Per Share Earnings over the last 28 years have been positive in 14 years.
Myriad Genetics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | MYGN |
| CUSIP: | 62855J |
| Website: | myriad.com |
Debt
| Debt-to-Equity Ratio: | 0.05 |
|---|---|
| Current Ratio: | 2.01 |
| Quick Ratio: | 1.64 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 80.15 |
MYGN Technical Analysis vs Fundamental Analysis
Sell
49
Myriad Genetics (MYGN)
is a Sell
Is Myriad Genetics a Buy or a Sell?
-
Myriad Genetics stock is rated a Sell
The current Myriad Genetics [MYGN] share price is $19.97. The Score for MYGN is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.